Magazine Article | September 1, 2016

Companies To Watch: Quark Pharmaceuticals

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

SNAPSHOT
Quark Pharmaceuticals is a pioneer in RNA (ribonucleic acid) interference (RNAi), now with its own siRNA (small interfering RNA) drugs that block targeted disease-causing genes. It has two products in Phase 3 development — QPI- 1002 for delayed graft function and QPI-1007 for nonarteritic anterior ischemic optic neuropathy (NAION) — and a number of others in preclinical to Phase 2 development for a wide range of conditions.

YOU'VE REACHED THE LIMIT OF 2 FREE ARTICLES PER MONTH.
Subscribe now to continue reading
Subscribe today to continue reading this story and receive uninterrupted access to Life Science Leader online. Your subscription also includes Life Science Leader’s monthly magazine which covers key areas such as clinical research, outsourcing and pharmaceutical manufacturing.